Patents by Inventor Maher Albitar

Maher Albitar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9488656
    Abstract: Truncation variants of BCR-ABL mRNA that produces BCR-ABL proteins with a truncated C-terminus and its role in resistance to treatment with kinase inhibitors is described. Vectors for expressing the truncated gene products are described as well as recombinant cells that express the truncated gene products from cDNA constructs. Also provided are methods compositions and kits for detecting the BCR-ABL truncation variants. Also provided are methods for determining the prognosis of a patient diagnosed as having myeloproliferative disease, and methods for predicting the likelihood for resistance to a treatment with tyrosine kinase inhibitor in a patient diagnosed as having myeloproliferative disease. Additionally, methods for screening BCR-ABL tyrosine kinase domain inhibitors which rely on the recombinant cells are also disclosed.
    Type: Grant
    Filed: September 28, 2010
    Date of Patent: November 8, 2016
    Assignee: QUEST DIAGNOSTICS INVESTMENTS INCORPORATED
    Inventors: Maher Albitar, Wanlong Ma
  • Publication number: 20160281172
    Abstract: The invention disclosed herein is based on the identification of novel mutations in the JAK2 gene and JAK2 protein. The invention provides compositions and methods useful for diagnosing hematopoietic diseases including, for example, myeloproliferative diseases. The invention also provides compositions and methods useful for determining a prognosis of an individual diagnosed as having a hematopoietic disease.
    Type: Application
    Filed: February 26, 2016
    Publication date: September 29, 2016
    Applicant: Quest Diagnostics Investments Incorporated
    Inventors: Maher Albitar, Wanlong Ma
  • Patent number: 9404159
    Abstract: Described herein are methods, compositions and kits directed to the detection the 5? portion of TMPRSS2 mRNA for the detection and diagnosis of prostate disease including prostate cancer and benign prostatic hyperplasia.
    Type: Grant
    Filed: September 9, 2013
    Date of Patent: August 2, 2016
    Assignee: QUEST DIAGNOSTICS INVESTEMENTS INCORPORATED
    Inventors: Heather R. Sanders, Maher Albitar
  • Publication number: 20160201141
    Abstract: The invention provides methods for determining the prognosis of a patient diagnosed with a leukemia, including B-cell chronic lymphocytic leukemia, by measuring mutations of the WT1 gene in a biological sample. The invention also relates to the diagnosis of leukemia, including B-cell chronic lymphocytic leukemia.
    Type: Application
    Filed: December 10, 2015
    Publication date: July 14, 2016
    Applicant: Quest Diagnostics Investments Incorporated
    Inventors: Maher Albitar, Wanlong Ma
  • Patent number: 9378407
    Abstract: An automated reader for reading fluorescence in-situ hybridization signals includes one or more computer processors for receiving a digitized FISH image and executing the steps of converting colors within the image to a hue value, separately for each color extracting quantitative values to detect the presence of signals corresponding to spots and applying a plurality of algorithms to extract features from the signals to determine cell shapes and segment cells within the FISH image. After recombining the signals, the extracted features for the colors learning machines are used to classify the spots according to the color and separate merged signals of classified spots that are in close proximity to each other within the image. The classified spots are counted to determine relative frequency of colors and a report is generated providing the number of classified spots of each color.
    Type: Grant
    Filed: September 11, 2013
    Date of Patent: June 28, 2016
    Assignee: Neogenomics Laboratories, Inc.
    Inventors: Hong Zhang, Maher Albitar
  • Publication number: 20160169786
    Abstract: An automated method and system are provided for receiving an input of flow cytometry data and analyzing the data using a hierarchical arrangement of analytical elements, each of which utilizes a support vector machine to automatically classify the data into different subpopulations to recognize a pattern within the data. The pattern may be used to generate a diagnostic prediction for a patient or to identify patterns within samples collected from multiple subjects.
    Type: Application
    Filed: December 10, 2015
    Publication date: June 16, 2016
    Inventors: Maher ALBITAR, Hong ZHANG
  • Publication number: 20160160289
    Abstract: The present disclosure relates to methods for the diagnosis and evaluation of neoplastic disorders, particularly non-small cell lung cancer. Assays are described in which patient test samples are analyzed for the presence of one or more specific EML4-ALK fusion genes associated with neoplastic disorders.
    Type: Application
    Filed: October 30, 2015
    Publication date: June 9, 2016
    Applicant: Quest Diagnostics Investments Incorporated
    Inventors: Heather R. Sanders, Maher Albitar, Aurelia Meloni-Ehrig
  • Publication number: 20160130648
    Abstract: Methods are provided for treating, managing, diagnosing and monitoring myelodysplastic syndrome and other hematologic malignancies. These methods comprise the next generation sequencing analysis conducted on cell-free DNA from peripheral blood plasma or serum.
    Type: Application
    Filed: November 11, 2015
    Publication date: May 12, 2016
    Inventor: Maher Albitar
  • Publication number: 20160130664
    Abstract: Compositions and fragment length analysis methods are provided for detecting CALR mutations and determining tumor load in patients with myeloproliferative neoplasms.
    Type: Application
    Filed: November 11, 2015
    Publication date: May 12, 2016
    Inventor: Maher Albitar
  • Patent number: 9336430
    Abstract: A system and method for computer-assisted karyotyping includes a processor which receives a digitized image of metaphase chromosomes for processing in an image processing module and a classifier module. The image processing module may include a segmenting function for extracting individual chromosome images, a bend correcting function for straightening images of chromosomes that are bent or curved and a feature selection function for distinguishing between chromosome bands. The classifier module, which may be one or more trained kernel-based learning machines, receives the processed image and generates a classification of the image as normal or abnormal.
    Type: Grant
    Filed: June 19, 2013
    Date of Patent: May 10, 2016
    Assignee: Health Discovery Corporation
    Inventors: Hong Zhang, Maher Albitar
  • Publication number: 20160123985
    Abstract: The present invention provides methods of classifying cluster of differentiation (CD) marker phenotype for hematopoietic cancer cells using multiple circulating cell-free CD markers in bodily fluid. In other aspects, treatment and disease progression of particular hematopoietic cancers can be monitored by measuring the levels of CD and other markers in bodily fluids of a patient.
    Type: Application
    Filed: January 11, 2016
    Publication date: May 5, 2016
    Applicant: Quest Diagnostics Investments Incorporated
    Inventor: Maher Albitar
  • Publication number: 20160069902
    Abstract: The present invention relates to the field of immunology and hyperproliferative diseases. More specifically, the present invention relates to a method of detecting and monitoring therapeutic antibody:antigen complex, soluble antigen and soluble therapeutic antibody, wherein a patient has undergone at least one course of immunotherapy. Yet further, levels of therapeutic antibody:antigen complexes, soluble antigens or soluble therapeutic antibodies may be measured and used to stage or monitor a hyperproliferative disease.
    Type: Application
    Filed: September 15, 2015
    Publication date: March 10, 2016
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Maher ALBITAR, Michael J. KEATING, Taghi MANSHOURI
  • Patent number: 9255926
    Abstract: The present invention provides methods of classifying cluster of differentiation (CD) marker phenotype for hematopoietic cancer cells using multiple circulating cell-free CD markers in bodily fluid. In other aspects, treatment and disease progression of particular hematopoietic cancers can be monitored by measuring the levels of CD and other markers i bodily fluids of a patient.
    Type: Grant
    Filed: August 17, 2006
    Date of Patent: February 9, 2016
    Assignee: QUEST DIAGNOSTICS INVESTMENTS INCORPORATED
    Inventor: Maher Albitar
  • Patent number: 9187788
    Abstract: Described herein are methods, compositions and kits directed to the detection of gene dysregulations such as those arising from gene fusions and/or chromosomal abnormalities, e.g., translocations, insertions, inversions and deletions. Samples containing dysregulated gene(s) of interest may show independent expression patterns for the 5? and 3? regions of the gene. The methods, compositions and kits are useful for detecting mutations that cause the differential expression of a 5? portion of a target gene relative to the 3? region of the target gene.
    Type: Grant
    Filed: August 7, 2014
    Date of Patent: November 17, 2015
    Assignee: QUEST DIAGNOSTICS INVESTMENTS INCORPORATED
    Inventors: Heather R. Sanders, Maher Albitar, Aurelia Meloni-Ehrig
  • Publication number: 20150315658
    Abstract: Described herein are methods, compositions and kits directed to the detection of gene dysregulations such as those arising from gene fusions and/or chromosomal abnormalities, e.g., translocations, insertions, inversions and deletions. Samples containing dysregulated gene(s) of interest may show independent expression patterns for the 5? and 3? regions of the gene. The methods, compositions and kits are useful for detecting mutations that cause the differential expression of a 5? portion of a target gene relative to the 3? region of the target gene.
    Type: Application
    Filed: April 29, 2015
    Publication date: November 5, 2015
    Applicant: Quest Diagnostics Investments Incorporated
    Inventors: Heather R. Sanders, Maher Albitar, Aurelia Meloni-Ehrig
  • Patent number: 9157916
    Abstract: The present invention relates to the field of immunology and hyperproliferative diseases. More specifically, the present invention relates to a method of detecting and monitoring therapeutic antibody:antigen complex, soluble antigen and soluble therapeutic antibody, wherein a patient has undergone at least one course of immunotherapy. Yet further, levels of therapeutic antibody:antigen complexes, soluble antigens or soluble therapeutic antibodies may be measured and used to stage or monitor a hyperproliferative disease.
    Type: Grant
    Filed: June 16, 2014
    Date of Patent: October 13, 2015
    Assignee: Board of Regents, The University of Texas Systems
    Inventors: Maher Albitar, Michael J. Keating, Taghi Manshouri
  • Publication number: 20150080255
    Abstract: The invention provides compositions and methods for diagnosing a patient as having a myeloproliferative disease by identifying mutations in the MPL gene or gene products.
    Type: Application
    Filed: September 22, 2014
    Publication date: March 19, 2015
    Applicant: Quest Diagnostics Investments Incorporated
    Inventors: Wanlong Ma, Maher Albitar
  • Publication number: 20150038367
    Abstract: Described herein are methods, compositions and kits directed to the detection of gene dysregulations such as those arising from gene fusions and/or chromosomal abnormalities, e.g., translocations, insertions, inversions and deletions. Samples containing dysregulated gene(s) of interest may show independent expression patterns for the 5? and 3? regions of the gene. The methods, compositions and kits are useful for detecting mutations that cause the differential expression of a 5? portion of a target gene relative to the 3? region of the target gene.
    Type: Application
    Filed: August 7, 2014
    Publication date: February 5, 2015
    Applicant: Quest Diagnostics Investments Incorporated
    Inventors: Heather R. Sanders, Maher Albitar, Aurelia Meloni-Ehrig
  • Publication number: 20140336280
    Abstract: The present disclosure provides methods of detecting and determining the aggressiveness of prostate cancer. These methods can be used to determine whether or not a patient needs a biopsy as well as guide treatment selection.
    Type: Application
    Filed: March 13, 2014
    Publication date: November 13, 2014
    Applicant: NEOGENOMICS LABORATORIES, INC.
    Inventor: Maher ALBITAR
  • Publication number: 20140335549
    Abstract: The present invention relates to the field of immunology and hyperproliferative diseases. More specifically, the present invention relates to a method of detecting and monitoring therapeutic antibody:antigen complex, soluble antigen and soluble therapeutic antibody, wherein a patient has undergone at least one course of immunotherapy. Yet further, levels of therapeutic antibody:antigen complexes, soluble antigens or soluble therapeutic antibodies may be measured and used to stage or monitor a hyperproliferative disease.
    Type: Application
    Filed: June 16, 2014
    Publication date: November 13, 2014
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Maher ALBITAR, Michael J. KEATING, Taghi MANSHOURI